CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 200 target
Drug / intervention
Zanidatamabdrug
Likely dose
Not stated in record
Key inclusion· 14
  • ✓At least 18 years of age
  • ✓Locally advanced, unresectable, or metastatic solid tumors with progression after at least 1 prior systemic treatment for metastatic or advanced disease
  • ✓No available treatment options with confirmed benefit
  • ✓HER2 overexpression IHC 3+ by central laboratory
Key exclusion· 18
  • ✕Known or suspected leptomeningeal disease and/or untreated brain metastasis
  • ✕Uncontrolled or significant cardiovascular disease
  • ✕Ongoing toxicity related to prior cancer therapy
  • ✕Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06695845
NCT06695845Phase 2RecruitingHigh Momentum
CompareCT.gov

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Jazz Pharmaceuticals·interventional·Posted Nov 19, 2024·Updated Jun 9, 2026

In Brief

A Phase 2 clinical trial evaluating Zanidatamab for Breast Cancer and 11 related conditions. Currently recruiting, targeting 200 participants across 28 sites in 3 countries.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
CountriesSouth Korea, Spain, United States
CollaboratorsJazz Pharmaceuticals Ireland Limited

Timeline

Phase 2Recruiting
2025202620272028
First PostedNov 19, 2024
Enrollment StartJan 14, 2025
Primary CompletionDec 31, 2026
Study CompletionDec 31, 2027
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 1.6 years agoPrimary completion in 6 months

Arms & Interventions

Zanidatamab treatment armexperimental

Eligible participants receiving zanidatamab treatment

Drug: Zanidatamab

Interventions

Zanidatamabdrug

Administered by intravenous (IV) infusion